SecBot SecBot

ARGX drug pipeline

ARGENX SE · 9 rated drugs
$960.04
−2.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±6.9%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
9
1 bullish · 8 neutral
Phase 3 trials
7
2 with results posted

Upcoming catalysts

1 dated
  1. Nov 2026
    empasiprubart
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketSeveral years away, if successful. Phase 3 MMN trial won't complete final data collection until December 2029. A potential BLA submission would follow positive Phase 3 data, likely no earlier than 2027-2028.

empasiprubart Updated Aug 22

What to watch

Watch for Phase 3 topline MMN data (estimated primary completion Sep 2026). Positive data could add a new pipeline pillar, but empasiprubart is not the primary value driver at argenx, Vyvgart's commercial trajectory and the myositis readout for efgartigimod are larger stock-moving events. A Phase 2 dermatomyositis readout is also expected by November 2026.

Bull case
  • Empasiprubart targets large, underserved autoimmune markets (MMN has no approved drug; dermatomyositis has limited options) where a successful IVIg alternative could carve a significant niche.
  • The Phase 3 MMN head-to-head vs IVIg is a high bar, but a win would rapidly establish empasiprubart as a standard-of-care challenger in a $1B+ addressable market.
  • argenx has a strong commercial infrastructure and deep immunology expertise from Vyvgart, enabling a swift launch if data support approval.
Bear case
  • Empasiprubart is a small piece of the argenx story, Vyvgart generates ~$1.5B/quarter. Even a successful Phase 3 readout would be a modest driver for a ~$1,040 stock with 23 analysts already rating it Buy.
  • The Phase 3 MMN trial is a head-to-head versus established IVIg therapy. Competitive efficacy and safety data are required to win share, a high bar for a novel complement inhibitor.
  • The Phase 2 dermatomyositis study enrolled only 3 patients, far too small for any efficacy signal, making it very early-stage and high-risk.
▲ bullish
Impact
PhaseApproved (Phase 3 for pipeline expansion)
Time to marketAlready FDA-approved and commercialized (December 2021 for gMG). Pipeline expansion into autoimmune myositis is in regulatory submission phase following positive Phase 3 data.

efgartigimod efgartigimod alfa Updated Aug 22

What to watch

Watch for argenx's regulatory filing for efgartigimod in autoimmune myositis following the positive Phase 3 ALKIVIA readout (Aug 17, 2026), that submission will unlock a PDUFA catalyst. Also track Vyvgart quarterly sales growth trajectory (60% YoY) as the key driver of earnings beats and estimate revisions.

Bull case
  • Efgartigimod (Vyvgart) is the first-in-class FcRn blocker approved for generalized myasthenia gravis and is generating rapidly growing commercial revenue, H1 2026 product net sales reached $1.5B (+60% YoY), with Q2 alone delivering $1.516B (+17% QoQ), beating consensus EPS by 19.4%.
  • Positive Phase 3 ALKIVIA trial results in autoimmune myositis (announced Aug 17, 2026) open a large new addressable market, with regulatory filing expected to follow, argenx's pipeline is expanding beyond gMG.
  • Analyst consensus is overwhelmingly bullish: 23 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of ~$1,173 implying ~13% upside from $1,040. EPS estimates have been revised upward consistently (8-11 upward revisions in the last 7 days alone).
Bear case
  • Competition in FcRn space is intensifying, UCB's rozanolixizumab (RYSTIGGO) and Johnson & Johnson's nipocalimab are approved or in late-stage testing for gMG and other indications, threatening market share and pricing.
  • Several Phase 3 trials for efgartigimod in new indications (thyroid eye disease, bullous pemphigoid) were terminated, raising questions about the breadth of the addressable pipeline beyond myositis and ITP.
  • The stock trades near its 52-week high (~$1,040, vs $1,059 high) with elevated short-volume ratios (consistently >55% in recent weeks), suggesting cautious positioning by some traders despite bullish fundamentals.
● neutral
Impact
PhasePhase 1b (proof-of-concept completed); Phase 2 (celiac disease) ongoing
Time to marketLikely 3-5+ years from 2026, pending Phase 2 celiac readout and Phase 3 development. FB102 is currently in Phase 1b/2-stage development with argenx's resources expected to accelerate the pipeline post-acquisition.

FB102 anti-CD122 antibody Updated Aug 22

What to watch

For ARGX investors, FB102 is a bolt-on pipeline asset that adds long-term optionality but is not a near-term binary driver given argenx's ~$53B market cap and $1.5B H1 2026 VYVGART revenue. Watch for Phase 2 celiac disease readout (H2 2026) and the deal closing (expected by late Q3). For FBRX holders, the stock trades near the $77 offer price, the arbitrage spread hinges on antitrust clearance and deal timing.

Bull case
  • First-in-class anti-CD122 antibody targeting T-cell/NK-cell mediated autoimmune diseases, a new mechanism distinct from argenx's FcRn franchise
  • Already has clinical proof-of-concept in two indications (vitiligo and celiac disease), de-risking the mechanism
  • FDA Fast Track designation for celiac disease accelerates regulatory pathway
Bear case
  • Still early-stage (Phase 1b/2), Phase 2 celiac data in H2 2026 could miss and wipe out much of the asset's value
  • Competitive T-cell modulation space includes other approaches (anti-IL-2, JAK inhibitors, etc.) that may prove more effective
  • Integration risk: argenx has no prior experience with T-cell/NK-cell targeted therapies, which differ from its FcRn-based platform
● neutral
Impact
PhasePhase 1
Time to marketUnknown — at least 5-7+ years if successful. The drug is only in Phase 1 testing (safety/PK in healthy volunteers), with no Phase 2 or Phase 3 trials initiated yet.

TSP-101 Updated Oct 24

What to watch

TSP-101 is a very early-stage (Phase 1) asset for argenx, representing a tiny fraction of the company's value. Argenx's near-term stock movement will be driven by its approved product Vyvgart and later-stage pipeline programs (ARGX-121, ARGX-124, ARGX-213), not TSP-101. Watch for Phase 1 safety/PK data readouts from Tensegrity Pharma, but these are unlikely to move ARGX shares materially.

Bull case
  • TSP-101 targets the Fn14/TWEAK pathway, a novel mechanism for cancer cachexia, a condition with high unmet medical need affecting a large population of cancer patients, with no approved targeted therapies.
  • Argenx's collaboration includes an option for future acquisition of Tensegrity Pharma, giving argenx a potential path to full ownership of the program if Phase 1 data are promising.
  • The drug has received support from AMED (Japan Agency for Medical Research and Development), providing non-dilutive funding and validation of the scientific approach.
Bear case
  • TSP-101 is only in Phase 1 testing, the vast majority of Phase 1 assets fail before reaching the market, and cancer cachexia is a notoriously difficult indication with no FDA-approved targeted therapies.
  • Argenx's involvement is through a research collaboration with an option to acquire Tensegrity Pharma, not direct development, argenx can walk away without significant financial damage, but that also means limited upside for ARGX shareholders from this asset.
  • The drug was originally discontinued by Astellas Pharma for strategic reasons before Tensegrity Pharma revived it, prior abandonment raises questions about the underlying science.
● neutral
Impact
PhasePreclinical / Discovery
Time to marketUnknown — likely 5+ years if it advances through preclinical development, IND-enabling studies, and clinical trials. The drug is not yet in clinical trials.

ARGX-109 Updated Oct 24

What to watch

ARGX-109 is a preclinical/early-discovery pipeline asset at argenx, a company overwhelmingly driven by its approved VYVGART franchise ($1.7B quarterly sales). This drug is too early-stage to move the stock independently. Investors should focus on argenx's near-term catalysts: Phase 3 empasiprubart MMN data (December 2026), the IMNM sBLA submission (year-end 2026), and the pediatric gMG PDUFA (February 2027).

Bull case
  • ARGX-109 is part of argenx's discovery pipeline, and argenx has a strong track record of advancing antibody-based therapies (VYVGART, empasiprubart) from research to approval, suggesting competent early-stage R&D.
  • argenx has $3.7B in cash and strong operating cash flow from VYVGART ($1.7B quarterly sales), providing ample resources to fund early-stage pipeline programs like ARGX-109 without dilution risk.
  • The drug was listed alongside other pipeline candidates in the Q3 2026 earnings filing, confirming it remains an active research program at the company.
Bear case
  • ARGX-109 is preclinical/early-discovery with no disclosed mechanism, target, or IND filing, essentially a research-stage concept with a very high probability of never reaching the market.
  • argenx's pipeline is broad (ARGX-213, ARGX-124, ARX-121, ARGX-118, ARGX-125, TSP-101, etc.), and early-stage programs compete for internal R&D resources; ARGX-109 could be deprioritized or discontinued without material disclosure.
  • No clinical trial data, no regulatory filings, and no scheduled catalysts exist for ARGX-109, making it uninvestable as a standalone thesis.
● neutral
Impact
PhaseUnknown — not found in any clinical trial registry or pipeline disclosure.
Time to marketUnknown — ARGX-118 cannot be identified in any public source. If it was a preclinical program, it would be years from potential approval, if pursued at all.

ARGX-118 Updated Oct 24

What to watch

ARGX-118 could not be identified in any available public database or internal source. Investors should verify the correct drug code, argenx's known pipeline includes ARGX-117 (complement inhibitor, Phase 2 completed), ARGX-119 (ALS, Phase 2 terminated), and approved VYVGART/efgartigimod. If ARGX-118 is a preclinical or discontinued program, it has no near-term catalyst value.

Bull case
  • argenx SE (ARGX) is a well-capitalized biotech with a ~$874 stock price, strong analyst consensus (23 Buy/Strong Buy vs 3 Hold), and a mean price target of ~$1,149 implying ~29% upside.
  • argenx's approved drug VYVGART (efgartigimod) is generating substantial revenue ($1.5B in Q2 2026 alone), funding a deep pipeline of immunology assets.
  • If ARGX-118 is an early-stage undisclosed program, it could represent a novel target in argenx's immunology franchise, but no public information exists to evaluate this.
Bear case
  • ARGX-118 is not found in any clinical trial registry, SEC filing, press release, or pipeline disclosure, it may be a discontinued, renamed, or never-publicly-disclosed program.
  • If ARGX-118 was a preclinical program that was terminated before entering the clinic, it has zero near-term value for investors.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

ARGX-124 Updated Oct 23

What to watch

"ARGX-124" could not be identified as an existing drug candidate in any public or internal database. Investors should verify the correct drug name or code before making any trading decisions. Argenx's known near-term catalysts are the myositis Phase 3 readout (expected Q3 2026) and the MMN Phase 3 readout (expected Q4 2026) for its approved/commercial-stage assets.

Bull case
  • No information available, drug could not be found in any available source.
Bear case
  • No information available, drug could not be found in any available source.
● neutral
Impact
PhasePreclinical / Discovery
Time to marketUnknown — likely 5+ years if it advances through clinical development, assuming it ever enters the clinic

ARGX-125 Updated Oct 24

What to watch

ARGX-125 is too early-stage and too small a part of argenx's pipeline to drive any share-price movement in the next 12 months. Investors should focus on argenx's major near-term catalysts: the Phase 3 EMPASSION (MMN) topline data for empasiprubart expected December 2026, the IMNM sBLA submission by year-end 2026, and the pediatric gMG PDUFA date in February 2027.

Bull case
  • ARGX-125 represents a potential future pipeline asset for argenx, a company with a strong track record in antibody therapeutics and FcRn biology
  • argenx has deep financial resources ($3.7B cash as of Q3 2026) to advance early-stage programs without dilutive financing
  • The ARGX-XXX naming convention suggests it is part of argenx's proprietary antibody pipeline, building on their established platform technology
Bear case
  • ARGX-125 is preclinical with no disclosed mechanism, target, or indication, essentially a 'black box' for investors
  • Preclinical drug candidates have a very high failure rate (>90%) before reaching market
  • As a tiny component of argenx's broad pipeline, even positive early data would have negligible impact on the stock price
● neutral
Impact
PhaseUnknown — no clinical trials or regulatory filings found for ARGX-213.
Time to marketUnknown — ARGX-213 has no publicly disclosed development status.

ARGX-213 Updated Oct 23

What to watch

ARGX-213 does not appear in any accessible clinical-trial registry, FDA database, press release, or pipeline disclosure for argenx. Investors should verify the drug name, it may be a preclinical internal code, a typo, or a candidate that was discontinued before public disclosure. Argenx's publicly disclosed pipeline (efgartigimod/VYVGART, empasiprubart/ARGX-117, ARGX-119, FB102) contains no ARGX-213.

Bull case
  • Argenx (ARGX) is a well-capitalized biotech ($5.2B cash per Q2 2026 earnings) with a strong track record in immunology, so any legitimate pipeline addition would benefit from deep expertise.
  • Analyst consensus is strongly bullish: 23 of 26 analysts rate Buy/Strong Buy, with a mean price target of ~$1,149 implying ~29% upside from $874.
Bear case
  • No evidence ARGX-213 exists as a disclosed argenx program, it may have been discontinued preclinically or never advanced.
  • Argenx's pipeline is heavily concentrated on efgartigimod (VYVGART); any undisclosed early candidate faces high preclinical failure risk.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Jun 20, 2023efgartigimodApproval−0.1%−5.0%
Dec 17, 2021efgartigimodApproval+13.6%+17.2%

Clinical trials

10 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
empasiprubartA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisPhase 2Active not recruiting3Nov 2026
empasiprubartA Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyPhase 3Active not recruiting154Sep 2026
ARGX-119A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Phase 2Terminated60Aug 12, 2026
EFG PH20 SCA Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.Phase 3Completed265Jul 2, 2026
efgartigimodA Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).Phase 3Completed101Mar 11, 2026
—A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.Phase 3Terminated105Dec 15, 2025
—A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseasePhase 3Terminated102Dec 15, 2025
efgartigimod PH20 SCA Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidPhase 3Terminated · results64Mar 20, 2025
ARGX-117A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyPhase 2Completed · results54Jun 4, 2024
Efgartigimod IVAn Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia GravisPhase 3Completed · results69Aug 24, 2023